Surgical and medical therapy for pancreatic carcinoma
Surgical and medical therapy for pancreatic carcinoma
复制标题
DOI：
10.1053/bega.2002.0317
复制
发表时间：
2002-06-01
影响因子：
3.2
通讯作者：
Neoptolemos, JP
中科院分区：
文献类型：
--
作者：
Magee, CJ;Ghaneh, P;Neoptolemos, JP
胰腺导管腺癌的治疗进展包括内科和外科治疗的进展，放射学和重症监护等学科做出了重要贡献。在过去的十年里，已经进行了大规模的随机对照试验，证明了患者预后的改善。慢性胰腺炎、遗传性胰腺炎和各种家族性癌症综合征都会增加患胰腺癌的风险。胰腺癌的最佳治疗结果需要由区域专科单位的多学科团队进行管理。内窥镜下支架置入术、良好的止痛效果和补充胰酶是治疗晚期胰腺癌的基础。化疗可延长晚期胰腺癌患者的生存期，但使用5FU以外的药物效果甚微。如果可能的话，切除可以延长生命并提供最好的生活质量。辅助放化疗无济于事，但化疗可提高存活率。随着临床治疗的发展，阐明了胰腺癌背后的分子事件，这一知识指导了胰腺癌靶向治疗的引入。
Progress on the treatment of pancreatic ductal adenocarcinoma has involved advances in medical and surgical care with important contributions from disciplines such as radiology and intensive care. In the last decade large randomized controlled trials have been undertaken that demonstrate the improved patient outcomes. There is an increased risk of pancreatic cancer in chronic pancreatitis, hereditary pancreatitis and a variety of familial cancer syndromes. The optimum outcome from pancreatic cancer needs management by multidisciplinary teams in regional specialist units. Endoscopic stenting, good pain relief and pancreatic enzyme supplementation are the basis of care in advanced pancreatic cancer. Chemotherapy prolongs survival in advanced pancreatic cancer with little to be gained using drugs other than 5FU. Resection, if possible, prolongs life and provides the best quality of life. Adjuvant chemoradiotherapy is of no benefit but chemotherapy may improve survival. Alongside the evolution in clinical management has been the elucidation of the molecular events that underlie pancreatic cancer and this knowledge has guided the introduction of targeted treatments for pancreatic cancer.